NCT04278768 2026-03-19
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Curis, Inc.
Phase 1/2 Suspended
Clinical Trials
31 trialsNCT06802523 2026-03-19
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Suspended
NCT03494569 2026-03-18
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Suspended
NCT04301076 2026-03-18
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06626633 2026-03-12
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
University of Maryland, Baltimore
Phase 1 Suspended
NCT03467386 2026-02-17
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Suspended
NCT06492707 2026-02-09
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Fred Hutchinson Cancer Center
Phase 1 Suspended
NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT05955261 2025-12-09
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Suspended
NCT05405387 2025-12-03
IMPACT
University of Utah
Phase 2 Suspended
NCT06709131 2025-11-24
CT0991
Zhejiang University
Phase 1 Suspended
NCT06454409 2025-11-19
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Suspended
NCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended
NCT06940570 2025-10-23
MATCH
University of Texas Southwestern Medical Center
Phase 3 Suspended
NCT06639958 2025-08-29
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
Children's Oncology Group
Phase NA Suspended
NCT05168904 2024-02-08
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Suspended
NCT04996030 2024-01-23
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Syros Pharmaceuticals
Phase 1 Suspended
NCT04828174 2023-11-29
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1 Suspended
NCT04485052 2023-10-23
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Suspended
NCT03229876 2023-07-24
Safety and Efficacy Evaluation of CD19-UCART
Bioray Laboratories
Phase NA Suspended
NCT01982175 2022-06-21
CLL004
Shanghai Zhangjiang Biotechnology Limited Company
Phase 2 Suspended
NCT02910752 2021-11-26
CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation
Shanghai Jiao Tong University School of Medicine
Phase 1/2 Suspended
NCT03722186 2021-03-22
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Suspended
NCT01755325 2018-04-25
Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+
Ruijin Hospital
Phase 3 Suspended
NCT02462265 2018-04-18
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Oshadi Drug Administration
Phase 2 Suspended
NCT01211691 2015-11-17
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Humanigen, Inc.
Phase 1/2 Suspended
NCT01010373 2015-02-10
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
BioMAS Ltd
Phase 2 Suspended
NCT02117336 2014-09-03
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Piramal Enterprises Limited
Phase 1 Suspended
NCT01222013 2013-03-26
Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Hospital Santa Marcelina
Phase 2 Suspended
NCT00991744 2012-10-10
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Nordic Society for Pediatric Hematology and Oncology
Phase 3 Suspended
NCT00077493 2007-12-28
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
Phase 1 Suspended